PT  - JOURNAL ARTICLE
AU  - Dinesh Khanna
AU  - Shikha Mittoo
AU  - Rohit Aggarwal
AU  - Susanna M. Proudman
AU  - Nicola Dalbeth
AU  - Eric L. Matteson
AU  - Kevin Brown
AU  - Kevin Flaherty
AU  - Athol U. Wells
AU  - James R. Seibold
AU  - Vibeke Strand
TI  - Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group
AID  - 10.3899/jrheum.141182
DP  - 2015 Nov 01
TA  - The Journal of Rheumatology
PG  - 2168--2171
VI  - 42
IP  - 11
4099  - http://www.jrheum.org/content/42/11/2168.short
4100  - http://www.jrheum.org/content/42/11/2168.full
SO  - J Rheumatol2015 Nov 01; 42
AB  - Objective. Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research.Methods. The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as ≥ 75% agreement among the participants.Results. OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as ≥ 10% relative decline in forced vital capacity (FVC) or ≥ 5% to < 10% relative decline in FVC and ≥ 15% relative decline in DLCO.Conclusion. There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.